Kura Oncology KURA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $39.08M-23.8% | $149.1M-33.6% | $95.29M+92.6% | $81.95M+81.4% | $51.27M+23.5% | ||
| $541.74M-10.7% | $518.14M+3.0% | $454.38M+12.0% | $548.78M+23.0% | $606.92M+25.0% | ||
| $9.35M-80.8% | $8.8M+327% | $35.94M+6,878% | $4.57M+788% | $48.75M+9,365% | ||
| $1.46M+1,316% | $722.75K— | $309.75K— | $206.5K— | $103.25K— | ||
| $32.77M+89.8% | $32.21M+109% | $35.06M+344% | $24.77M+200% | $17.26M+61.1% | ||
| $623.78M-13.9% | $708.66M-4.9% | $620.66M+34.0% | $660.08M+32.1% | $724.2M+34.7% | ||
| $7.61M+224% | $7.86M+367% | $7.4M+463% | $3.91M+157% | $2.35M+37.4% | ||
| $7.17M-12.0% | $7.3M+25.8% | $7.54M+23.6% | $7.86M+22.9% | $8.14M+21.5% | ||
| $13.99M+54.1% | $14.54M+85.4% | $13.78M+67.4% | $10.57M+42.4% | $9.08M+18.4% | ||
| $652.55M-12.3% | $738.36M-2.9% | $649.38M+35.6% | $682.43M+32.5% | $743.76M+34.3% | ||
| $7.04M-84.4% | $5.02M+242% | $66.79M+80.7% | $52.93M+70.0% | $45.09M+45.9% | ||
| —— | —— | —— | —— | —— | ||
| $47.7M— | $48.98M— | $48.75M— | —— | —— | ||
| —— | $0— | $4.34M— | $3.11M— | $1.92M— | ||
| $1.28M-32.7% | $1.28M-32.1% | $1.43M-15.5% | $1.7M+15.6% | $1.91M+39.8% | ||
| $416.75M— | $424.91M— | $268.85M— | —— | —— | ||
| $101.5M+13.1% | $116.97M+48.6% | $121.3M+200% | $107.17M+220% | $89.77M+178% | ||
| $9.75M+27.4% | $9.71M+40.4% | $5.34M-31.2% | $6.51M-24.1% | $7.65M-18.4% | ||
| $13.24M+68.1% | $9.47M+82.4% | $8.36M+53.0% | $8.16M+39.6% | $7.88M+26.4% | ||
| $14.52M+48.5% | $10.75M+52.0% | $9.79M+36.8% | $9.85M+34.8% | $9.78M+28.8% | ||
| $3.44M+60.7% | $3.17M+76.3% | $2.98M+103% | $2.6M+121% | $2.14M+125% | ||
| $544.67M+43.6% | $564.23M+62.8% | $406.84M+639% | $376.94M+669% | $379.36M+677% | ||
| $9K+12.5% | $9K+12.5% | $9K+12.5% | $9K+12.5% | $8K0.0% | ||
| $1.36B+3.0% | $1.35B+3.0% | $1.33B+2.8% | $1.32B+2.7% | $1.32B+3.1% | ||
| -$1.25B-30.9% | -$1.17B-31.1% | -$1.09B-24.8% | -$1.02B-24.0% | -$952.85M-23.6% | ||
| -$380K-139% | $1.02M+34.0% | $918K-17.7% | $711K+254% | $974K+219% | ||
| $107.88M-70.4% | $174.14M-57.9% | $242.54M-42.8% | $305.49M-34.5% | $364.41M-27.9% | ||
| $652.55M-12.3% | $738.36M-2.9% | $649.38M+35.6% | $682.43M+32.5% | $743.76M+34.3% | ||
| $541.74M-10.7% | $518.14M+3.0% | $454.38M+12.0% | $548.78M+23.0% | $606.92M+25.0% | ||
| $13.99M+54.1% | $14.54M+85.4% | $13.78M+67.4% | $10.57M+42.4% | $9.08M+18.4% | ||
| $7.17M-12.0% | $7.3M+25.8% | $7.54M+23.6% | $7.86M+22.9% | $8.14M+21.5% | ||
| $7.17M-12.0% | $7.3M+25.8% | $7.54M+23.6% | $7.86M+22.9% | $8.14M+21.5% | ||
| $13.99M+54.1% | $14.54M+85.4% | $13.78M+67.4% | $10.57M+42.4% | $9.08M+18.4% | ||
| $7.17M-12.0% | $7.3M+25.8% | $7.54M+23.6% | $7.86M+22.9% | $8.14M+21.5% | ||
| $13.99M+54.1% | $14.54M+85.4% | $13.78M+67.4% | $10.57M+42.4% | $9.08M+18.4% | ||
| $416.75M— | $424.91M— | $268.85M— | —— | —— | ||
| $416.75M— | $424.91M— | $268.85M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $416.75M— | $424.91M— | $268.85M— | —— | —— | ||
| $24.27M+25.4% | $20.46M+23.3% | $19.47M+17.1% | $19.47M+16.4% | $19.35M+14.0% | ||
| —— | —— | —— | —— | —— | ||
| $1.36B+3.0% | $1.35B+3.0% | $1.33B+2.8% | $1.32B+2.7% | $1.32B+3.1% | ||
| $9K+12.5% | $9K+12.5% | $9K+12.5% | $9K+12.5% | $8K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kura Oncology's total assets?
- Kura Oncology (KURA) holds $652.6M in total assets, down 12.3% year over year.
- How much debt does Kura Oncology have?
- Kura Oncology carries $24.3M in total debt against $107.9M of shareholders' equity, a debt-to-equity ratio of 0.23.
- How much cash does Kura Oncology have?
- Kura Oncology holds $39.1M in cash and equivalents.
- Can Kura Oncology cover its short-term obligations?
- Its current ratio is 6.15 — current assets exceed current liabilities.
- Where does Kura Oncology's balance sheet data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
